Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

被引：0
|
作者：
Kris, M. G. [1 ]
Riely, G. J. [1 ]
Azzoli, C. G. [1 ]
Heelan, R. T. [1 ]
Krug, L. M. [1 ]
Pao, W. [1 ]
Milton, D. T. [1 ]
Moore, E. [1 ]
Rizvi, N. A. [1 ]
Miller, V. A. [1 ]
机构：
[1] Memor Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7575
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pemetrexed monotherapy in patients with advanced non-small cell lung cancer who have had prior chemotherapy: A prospective phase II trial
    Lee, H.
    Ahn, M.
    Ahn, J.
    Kwon, J.
    Lee, S.
    Bae, S.
    Kim, B.
    Kim, H.
    Hong, D.
    Park, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds
    Huang, Yu
    Chen, Yu
    Mei, Qin
    Chen, Yuan
    Yu, Shiying
    Xia, Shu
    ONCOLOGY REPORTS, 2013, 29 (06) : 2486 - 2492
  • [43] mTORC1 inhibitor RAD001(everolimus)enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition
    Yu Chen
    Wen-wen LI
    Ping Peng
    Wei-heng Zhao
    Yi-jun Tian
    Yu Huang
    Shu Xia
    Yuan Chen
    Acta Pharmacologica Sinica, 2019, (08) : 1085 - 1094
  • [44] Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial
    Riudavets, Mariona
    Naigeon, Marie
    Texier, Matthieu
    Dorta, Miriam
    Barlesi, Fabrice
    Mazieres, Julien
    Varga, Andrea
    Cassard, Lydie
    Boselli, Lisa
    Grivel, Jonathan
    NgoCamus, Maud
    Lacroix, Ludovic
    Mezquita, Laura
    Besse, Benjamin
    Chaput, Nathalie
    Planchard, David
    LUNG CANCER, 2022, 166 : 255 - 264
  • [45] mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition
    Chen, Yu
    Li, Wen-wen
    Peng, Ping
    Zhao, Wei-heng
    Tian, Yi-jun
    Huang, Yu
    Xia, Shu
    Chen, Yuan
    ACTA PHARMACOLOGICA SINICA, 2019, 40 (08) : 1085 - 1094
  • [46] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    J J Yang
    Q Zhou
    H H Yan
    X C Zhang
    H J Chen
    H Y Tu
    Z Wang
    C R Xu
    J Su
    B C Wang
    B Y Jiang
    X Y Bai
    W Z Zhong
    X N Yang
    Y L Wu
    British Journal of Cancer, 2017, 116 : 568 - 574
  • [47] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    Yang, J. J.
    Zhou, Q.
    Yan, H. H.
    Zhang, X. C.
    Chen, H. J.
    Tu, H. Y.
    Wang, Z.
    Xu, C. R.
    Su, J.
    Wang, B. C.
    Jiang, B. Y.
    Bai, X. Y.
    Zhong, W. Z.
    Yang, X. N.
    Wu, Y. L.
    BRITISH JOURNAL OF CANCER, 2017, 116 (05) : 568 - 574
  • [48] Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate)
    Mersiades, Antony
    Pavlakis, Nick
    Kao, Steven
    John, Tom
    Lee, Chee Khoon
    Dawson, Sarah-Jane
    Wong, Stephen
    Tan, Lavinia
    Yip, Sonia
    Brown, Chris
    Livingstone, Ann
    Cheung, Yvonne
    Jurkovic, Hannora
    Stockler, Martin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 199 - 200
  • [49] Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
    Lee, Dae Ho
    Park, Keunchil
    Kim, Joo Hang
    Lee, Jong-Seok
    Shin, Sang Won
    Kang, Jin-Hyoung
    Ahn, Myung-Ju
    Ahn, Jin Seok
    Suh, Cheolwon
    Kim, Sang-We
    CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1307 - 1314
  • [50] Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer
    Adjei, Alex A.
    Molina, Julian R.
    Mandrekar, Sumithra J.
    Marks, Randolph
    Reid, Joel R.
    Croghan, Gary
    Hanson, Lorelei J.
    Jett, James R.
    Xia, Chenghua
    Lathia, Chetan
    Simantov, Ronit
    CLINICAL CANCER RESEARCH, 2007, 13 (09) : 2684 - 2691
12345